All of Us Research Program
Do you want to change the future of health? The Froedtert & MCW health network is part of the National Institutes of Health All of Us Research Program. It has a simple mission — speed up health research breakthroughs. To do this, All of Us is asking one million people to share their health information. Learn how you can help make a difference by joining the All of Us Research Program.
A Randomized, Double-blind, Phase 3 Study of Tucatinib or Placebo in Combination with Trastuzumab and Pertuzumab as Maintenance Therapy for Metastatic HER2+ Breast Cancer (HER2CLIMB-05)
MRI Brain Surveillance Alone Versus MRI Surveillance and Prophylactic Cranial Irradiation (PCI): A Randomized Phase III Trial in Small-Cell Lung Cancer (MAVERICK)
Phase III Trial of Stereotactic Radiosurgery (SRS) versus Hippocampal-Avoidant Whole Brain Radiotherapy (HA-WBRT) for 10 or fewer Brain Metastases from Small Cell Lung Cancer
A Phase II/III Study of N-803 (ALT-803) Plus Pembrolizumab Versus Standard of Care in Participants with Stage IV or Recurrent Non-Small Cell Lung Cancer Previously Treated with Anti-PD-1 or Anti-PD-L1 Therapy (Lung-MAP Non-Match Sub-Study)
Treatment (N-803 (ALT-803) plus Pembrolizumab) against the Usual Treatment
for Advanced Non-Small Cell Lung Cancer
Transdermal Buprenorphine for the Treatment of Radiation Induced Mucositis Pain in Head & Neck Cancer Patients: A Pilot Study
A Phase I Study of MR-Guided Dose-Escalated Hypofractionated Adaptive Radiation Therapy and Immunotherapy in Primary Metastatic or Very Locally Advanced Patients with Head and Neck Cancer
A Phase I Dose-Escalation Study of CPI-613 (Devimistat) in Combination with Chemoradiation in Patients with Pancreatic Adenocarcinoma
A Phase 1 Open-label, Safety, Pharmacokinetic and Preliminary Efficacy Study of STRO-002, an Anti-Folate Receptor alpha (FolRa) Antibody Drug Conjugate (ADC), in Combination with Bevacizumab in Patients with Advanced Epithelial Ovarian Cancer (Including Fallopian Tube or Primary Peritoneal Cancers)
A Phase Ib/II Study of Venetoclax (ABT-199) in Combination with Liposomal Vincristine in Patients with Relapsed or Refractory T-cell or B-cell Acute Lymphoblastic Leukemia
The Medical College of Wisconsin is conducting a study to understand how the hormones that control energy expenditure and food intake change during and after weight loss.
Salt sensitive hypertension is a significant health problem worldwide and a modifiable risk factor for renal, cardiovascular, and cerebrovascular diseases. This study aims to determine how kidney function (by measuring renal oxygenation and blood flow) and the process by which your body converts what you eat and drink into energy food (your metabolism) differs between individuals with and without salt sensitivity. A total of about 70 people between the ages of 25 and 65 with a blood pressure of 110/70 or higher are expected to participate in this at the Medical College of Wisconsin.
The purpose of this study is to better understand how microbes in our gut affect our resting metabolic rate (the amount energy expended at rest by our bodies) and body weight.